With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic
defects of cystic fibrosis (CF) commenced. Pharmacological manipulation provides the …

Rationale: As the life expectancy for individuals with cystic fibrosis (CF) continues to
improve, an emphasis on optimizing health-related quality of life (HRQoL) has become …

The chronic colonization of the lower airways by bacterial pathogens is the leading cause of
morbidity and mortality in patients with cystic fibrosis (CF). Pseudomonas aeruginosa is the …

Objective Cystic fibrosis associated liver disease (CFLD) is the third largest cause of
mortality in CF. Our aim was to define the burden of CFLD in the UK using national registry …

Objective: Depression is a known barrier to regimen adherence for chronic conditions.
Despite elevated depression rates and complex regimens for people with cystic fibrosis …

The prevalence of many chronic noncommunicable diseases has been steadily rising over
the past six decades. During this time, over 350,000 new chemical substances have been …

Survival in patients with cystic fibrosis (CF) has improved dramatically over the past 30 to 40
years, with mean survival now approximately 40 years. Nonetheless, progressive respiratory …

Background Osteoporosis is a bone mineralisation disorder occurring in about one third of
adults with cystic fibrosis. Bisphosphonates can increase bone mineral density and …

Cystic fibrosis (CF) represents one of a number of localized lung and non-lung diseases with
an intense chronic inflammatory component associated with evidence of systemic oxidative …

Cystic fibrosis (CF) is characterised by many comorbidities related to aberrant mucosa and
chronic inflammation in the respiratory and digestive systems. The intestinal mucosa serves …